# Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin

> **NCT03758235** · PHASE3 · UNKNOWN · sponsor: **University Of Perugia** · enrollment: 140 (actual)

## Conditions studied

- Overactive Bladder Syndrome

## Interventions

- **DRUG:** IncobotulinumtoxinA 100 UNT Injection [Xeomin]
- **DRUG:** OnabotulinumtoxinA 100 UNT [Botox]

## Key facts

- **NCT ID:** NCT03758235
- **Lead sponsor:** University Of Perugia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-01
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-09-01
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758235, "Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03758235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*